Cipla launches antibody detection kits for COVID-19 in India

29 Oct 2020 Evaluate

Cipla has launched antibody detection kits for COVID-19 in India under the brand name 'ELIFast' in partnership with KARWA, under the technology transfer from the Indian Council of Medical Research (ICMR). As part of the collaborative effort, the company will be responsible for the marketing and distribution of the SARS CoV-2-IgG antibody detection ELISA that will be manufactured by KARWA.

ICMR has provided the requisite technological know-how and process for developing the test kits to the approved manufacturers. The company's distribution network will help in ensuring the seamless supply of kits across the country. Supply will be undertaken through the channels approved by ICMR to ensure equitable access.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1498.90 -21.65 (-1.42%)
08-Dec-2025 15:42 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1272.70
Cipla 1498.90
Zydus Lifesciences 920.90
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×